In vitro invasion inhibition assay using antibodies against Plasmodium knowlesi Duffy binding protein alpha and apical membrane antigen protein 1 in human erythrocyte-adapted P. knowlesi A1-H.1 strain. by Muh, Fauzi et al.
Muh, F; Lee, SK; Hoque, MR; Han, JH; Park, JH; Firdaus, ER;
Moon, RW; Lau, YL; Han, ET (2018) In vitro invasion inhibition as-
say using antibodies against Plasmodium knowlesi Duffy binding pro-
tein alpha and apical membrane antigen protein 1 in human erythrocyte-
adapted P. knowlesi A1-H.1 strain. Malaria journal, 17 (1). p. 272.
ISSN 1475-2875 DOI: https://doi.org/10.1186/s12936-018-2420-4
Downloaded from: http://researchonline.lshtm.ac.uk/4648725/
DOI: 10.1186/s12936-018-2420-4
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
Muh et al. Malar J  (2018) 17:272  
https://doi.org/10.1186/s12936-018-2420-4
RESEARCH
In vitro invasion inhibition assay using 
antibodies against Plasmodium knowlesi 
Duffy binding protein alpha and apical 
membrane antigen protein 1 in human 
erythrocyte-adapted P. knowlesi A1-H.1 strain
Fauzi Muh1, Seong‑Kyun Lee1, Mohammad Rafiul Hoque1, Jin‑Hee Han1, Ji‑Hoon Park1, Egy Rahman Firdaus1, 
Robert W. Moon2, Yee Ling Lau3 and Eun‑Taek Han1* 
Abstract 
Background: The rapid process of malaria erythrocyte invasion involves ligand–receptor interactions. Inducing 
antibodies against specific ligands or receptors that abrogate the invasion process is a key challenge for blood stage 
vaccine development. However, few candidates were reported and remain to be validated for the discovery of new 
vaccine candidates in Plasmodium knowlesi.
Methods: In order to investigate the efficacy of pre‑clinical vaccine candidates in P. knowlesi‑infected human cases, 
this study describes an in vitro invasion inhibition assay, using a P. knowlesi strain adapted to in vitro growth in human 
erythrocytes, PkA1‑H.1. Recombinant proteins of P. knowlesi Duffy binding protein alpha (PkDBPα) and apical mem‑
brane antigen 1 (PkAMA1) were produced in Escherichia coli system and rabbit antibodies were generated from 
immune animals.
Results: PkDBPα and PkAMA1 recombinant proteins were expressed as insoluble and produced as a functional 
refolded form for this study. Antibodies against PkDBPα and PkAMA1 specifically recognized recombinant proteins 
and native parasite proteins in schizont‑stage parasites on the merozoite organelles. Single and combination of 
anti‑PkDBPα and anti‑PkAMA1 antibodies elicited strong growth inhibitory effects on the parasite in concentration‑
dependent manner. Meanwhile, IgG prevalence of PkDBPα and PkAMA1 were observed in 13.0 and 46.7% in human 
clinical patients, respectively.
Conclusion: These data provide support for the validation of in vitro growth inhibition assay using antibodies of 
DBPα and AMA1 in human‑adapted P. knowlesi parasite PkA1‑H.1 strain.
Keywords: Plasmodium knowlesi, Zoonotic malaria, PkDBPα, PkAMA1, Invasion, Inhibition
© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
Malaria Journal
*Correspondence:  ethan@kangwon.ac.kr; etaekhan@gmail.com 
†Fauzi Muh and Seong‑Kyun Lee are co‑first authors
1 Department of Medical Environmental Biology and Tropical Medicine, 
School of Medicine, Kangwon National University, Chuncheon, 
Gangwon‑do 24341, Republic of Korea
Full list of author information is available at the end of the article
Page 2 of 11Muh et al. Malar J  (2018) 17:272 
Background
Plasmodium knowlesi cases have now been reported in 
most countries in Southeast Asia with an epicenter of 
cases in Malaysia [1–3]. Until recently P. knowlesi cases 
were commonly misdiagnosed as P. malariae due to its 
similar morphology and less sensitive diagnostic tests, 
masking the extent of infections in the region [2, 4, 5]. 
Plasmodium knowlesi can cause severe disease in humans 
and life-threatening malaria cases have been reported 
[6]. Despite this, research into this parasite has been 
relatively neglected compared to other human malaria 
infections. The recent adaptation of P. knowlesi to human 
erythrocyte in  vitro culture has provided an important 
new tool to study parasite biology as well as the oppor-
tunity for new assays to test therapeutic interventions 
against this important parasite.
The Plasmodium life cycle is complex and involves 
ligand–receptor interactions for successful invasion and 
multiplication in host erythrocytes [7]. However, Plas-
modium vivax and P. knowlesi depend on the presence 
of the Duffy antigen receptor for chemokine (DARC) on 
erythrocytes for invasion. P. knowlesi Duffy binding pro-
tein alpha (PkDBPα) is a ligand for DARC and pivotal in 
human infection [8, 9]. Antibodies against domain II of 
PkDBPα or against surface-exposed DARC epitope inhib-
ited invasion of monkey and human erythrocytes [10]. 
While apical membrane antigen 1 (AMA1) is one of the 
polymorphic leading vaccine candidates, which involved 
in tight junction formation and essential for an invasion 
among Plasmodium species [11–14]. Anti-PkAMA1 
antibody inhibited erythrocyte invasion in an animal 
model [15]. The complex formed with the ectodomain of 
PkAMA1 (domain 1 and 2) and rhoptry neck protein 2 
(RON2) is essential for invasion and as compared to Plas-
modium falciparum and P. vivax, the RON2-binding site 
of PkAMA1 is much less polymorphic [13].
Few vaccine candidates directed to blood stage anti-
gens have been only evaluated to inhibit P. knowlesi inva-
sion into either monkey or human erythrocytes [16], 
such as PkDBPα [10] and PkAMA1 [14]. Antibodies play 
a major role in immunity to malaria by inhibiting the 
invasion into host red blood cells. Antibodies that abro-
gate invasion are extensively studied in P. falciparum and 
an association with protection against malaria could be 
shown [17, 18]. In P. vivax, the functional assessment of 
inhibitory antibodies is less well studied due to the lack of 
a continuous in vitro culture [19].
Invasion inhibition assays or growth inhibition assays 
have been designed to evaluate malaria vaccine can-
didates for P. falciparum and P. vivax [20–22]. A reli-
able, sensitive and validated invasion inhibition assay 
is required for evaluation of protective antibodies to 
malaria [17]. Several methods were used to determine 
parasitaemia for in  vitro growth inhibition assays, 
such as counting parasitaemia by Giemsa-staining and 
microscopy [23, 24], or measuring parasite lactate dehy-
drogenase (pLDH) activity [17, 25], but both have low 
sensitivity in the assessment of parasite invasion. Flow 
cytometry is a reliable and versatile technique and widely 
used because it is highly reproducible, efficient, and more 
robust than other methods [17, 26, 27]. Previous stud-
ies had shown the inhibitory effect of anti-PkDBPα and 
anti-PkAMA1 antibodies with different assays, such as 
for the presence of rings on Giemsa-stained smears and 
pLDH activity, respectively [10, 14]. To assess the poten-
tial of new vaccine candidates against the blood stages of 
P. knowlesi, a high throughput functional screening assay 
is required.
In this study, PkDBPα and PkAMA1 antigens were suc-
cessfully produced as correctly folded forms in Escheri-
chia coli system which is different from previous studies 
[10, 14] and antibodies raised from immune animals were 
validated in recognition of native parasite antigen with 
subcellular localization in blood-stage parasites. IgG 
prevalence was measured with knowlesi human clinical 
patients. Previous studies had described the invasion-
inhibitory activity of PkDBPα and PkAMA1 antibodies 
in P. knowlesi H strain with Giemsa-stained smears in 
presence of rings or parasite-specific lactate dehydroge-
nase (pLDH) activity assay [10, 14]. In this study, a flow 
cytometric based invasion inhibition assay was used to 
validate inhibitory antibodies to abrogate P. knowlesi 
invasion into human erythrocytes with human-adapted P. 
knowlesi PkA1-H.1 strain parasites and it may be useful 
for discovery of new antigenic and vaccine candidates in 
the future.
Methods
Patients’ sample information
Blood samples of clinical cases were collected in EDTA-
vacutainer from University of Malaya Medical Center 
(UMMC), Malaysia between 2010 and 2013 at day 0 (15 
patients; mean age 46  years, range 22–70  years; mean 
parasitaemia 0.18, range 0.03–0.30) [28]. Samples were 
centrifuged and the serum was separated. All P. knowlesi 
chosen for this study have been confirmed by micros-
copy and species-specific PCR as described elsewhere 
[5]. Serum was also collected from healthy individuals 
living in non-endemic areas of the Republic of Korea 
(ROK); these samples were used as a negative control. All 
experiments were performed in accordance with relevant 
guidelines and regulations and all experimental proto-
cols involving human samples approved by the Kangwon 
National University Hospital Ethical Committee (IRB No. 
2014-08-008-002) and the University of Malaya Medi-
cal Ethics Committee (Ref No. 817.18) and the Medical 
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Research Ethic Committee (MREC), Ministry of Health, 
Malaysia (National Medical Research Register ID No. 
13079). Informed consent was obtained from all subjects.
Parasite culture
Human-adapted P. knowlesi A1-H.1 strain was main-
tained with fresh human erythrocytes in RPMI-1640-
based medium (Invitrogen Life Technologies, Grand 
Island, NY) containing other components in addition of 
human AB serum as described previously [29].
Recombinant protein expression
The DNA fragment of PkDBPα-II was amplified from 
the P. knowlesi A1-H.1 strain with specific primers 
PkDBPα_F (actgatccatggTTA TTA ATC AAA CTT TTC 
TTC); PkDBPα_R (atagtttagcggccgcTCA GAG ATG ATG 
ATG ATG ATG TTC AGT TAT CGG ATT AA) as described 
previously [30]. Restriction enzymes, NcoI and NotI, 
were indicated as italicized and underlined letters. 
PkAMA1 domain I-II was amplified with specific prim-
ers; PkAMA1_F (ggtcgcggatccgaattcATG CCT ATC 
ATT GAG AGA AGT ATA CG) and PkAMA1_R (ggtg-
gtggtgctcgagTGG AAA TTC ATT GTC TAC TTC TTG 
AG). Restriction enzymes, XhoI and BamHI, were indi-
cated as italicized and underlined letters. PCR was run 
using a high-fidelity KDO-plus Kit (Toyobo Co., Osaka, 
Japan) with initial denaturation at 94  °C for 2  min, fol-
lowed by 35 cycles of 94  °C for 15  s, 60  °C for 30  s, 
and 58  °C for 1.5  min and a final extension at 68  °C 
for 10  min. The amplicons were purified using a gel 
extraction kit and ligated into the pET28a(+) expres-
sion vector (Novagen, Madison, WI) with His-tag. The 
obtained plasmid was confirmed by DNA sequenc-
ing analysis and transformed into E. coli Origami™ 
2(DE3) pLySs (Novagen) and BL21 (DE3) competent 
cells (Novagen) for PkDBPα and PkAMA1, respec-
tively. Recombinant proteins were induced with 0.1 mM 
isopropyl-β-d-thiogalactopyranoside (IPTG; Sigma-
Aldrich Co., St. Louis, MO). Protein solubilization, puri-
fication and refolding were described elsewhere [31]. The 
refolded proteins were eluted from ion exchange chroma-
tography (HiTrap™ SP FF; GE Healthcare Life Sciences) 
using gradient 0.2 and 1 M NaCl.
SDS‑PAGE and western blot analysis
Refolded proteins of DBPα-II and AMA1_DI-II of P. 
knowlesi were separated by 10% SDS-PAGE under 
reducing and non-reducing conditions and stained 
with 0.25% Coomassie brilliant blue R-250 (Sigma-
Aldrich Co.). Bovine serum albumin (BSA, 5 µg; Sigma-
Aldrich Co.) was used as positive control. Briefly, 2.5 µg 
refolded proteins and 5 µg bovine serum albumin (BSA) 
protein were incubated with 10  mM dithiothreitol 
(DTT, reduced condition), incubated at 37  °C for 1  h 
and added 2× loading dye containing reducing agent 
2-mercaptoethanol; 2.5 µg proteins and 5 µg BSA pro-
tein without DTT (non-reduced condition), added 
2× loading dye without reducing agent. Samples were 
heated at 95 °C for 4 min.
The parasite lysate was prepared as described previ-
ously [28]. Parasite lysate and recombinant proteins 
(0.5 μg) were separated by 13% SDS-PAGE under reduc-
ing condition. Membranes were transferred to a 0.45-µm 
polyvinylidene fluoride (PVDF) membrane (Millipore, 
Billerica, MA) in a semi-dry transfer apparatus (ATTO 
corp., Japan) at a current of 400  mA for 40  min. Mem-
brane-transferred proteins were reacted with primary 
anti-His (1:2000) monoclonal antibody, anti-rabbit anti-
bodies (1:2000, recombinant protein recognition or 1:50, 
parasite lysate recognition) and then reacted with sec-
ondary IRDye goat anti-mouse or goat anti-rabbit anti-
bodies (1:10,000) (LI-COR Bioscience, Lincoln, NE). The 
Odyssey infrared imaging system (LI-COR Bioscience) 
and Odyssey software (LI-COR Bioscience) were used to 
visualize the bands.
Antibody production and IgG purification
Immunization was conducted in Japanese white rabbit 
with 250  μg of folded recombinant proteins in Freund’s 
complete adjuvant followed by Freund’s incomplete adju-
vant in the 2-week interval. Rabbits were injected for 3 
times and serum samples were collected 2  weeks after 
final boost. Total IgGs were purified from 1  mL of rab-
bit serum by using protein G HP column according to the 
manufacturer’s protocol (GE Healthcare Life Sciences). 
The eluted IgGs fractions were dialyzed against incom-
plete RPMI1640 (Invitrogen Life Technologies) and con-
centrated with centrifugal devices 30  kDa cut-off value 
(Millipore, Billerica, MA). To remove any nonspecific 
inhibitory effect of IgGs, the purified IgGs were pread-
sorbed with human erythrocytes as described previously 
[22] with little modification (25  µL of erythrocytes per 
4 mg IgGs) for 30 min.
Immunofluorescence assay (IFA)
Schizont parasites of P. knowlesi were fixed with ice-cold 
acetone. Anti-PkDBPα and PkAMA1 (1:100) polyclonal 
serum were reacted as primary antibody and Alexa Fluor 
488-conjugated anti-rabbit (H + L) antibody (1:500, Invit-
rogen Life Technologies) was used as secondary antibody. 
The slides were visualized using a confocal laser scanning 
microscope (FV200 Olympus, Tokyo, Japan) equipped 
with 20× dry and 60× oil objectives. Images were cap-
tured using the FV10-ASW 3.0 viewer software.
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Protein microarray
Amine-coated slides were used and spotted in duplicate 
with 100 ng of purified recombinant proteins of PkDBPα 
or PkAMA1 at 37 °C for 2 h. After blocking with 5% BSA 
in PBS 0.1% Tween-20, knowlesi-infected patients’ serum 
and healthy individuals’ serum were reacted (1:25) for 
1  h. Alexa Fluor 546-conjugated goat anti-human IgG 
(10  µg/mL; Invitrogen Life Technologies) was used as 
a secondary antibody, and the fluorescence signal was 
detected with a scanner (InnoScan scanner, Carbonne, 
France). The cut-off values were set to the mean fluores-
cence intensity (MFI) plus 2 standard deviations (SDs). 
The normalized MFI was calculated by dividing the MFI 
by the cut-off value.
Growth inhibition assay (GIA)
Plasmodium knowlesi A1-H.1 schizonts were purified by 
using magnetic-activated cell sorting (MACS) technol-
ogy (Miltenyi Biotec, Bergisch Gladbach, Germany) with 
an LD column (Miltenyi Biotec) and cultured in 96-well 
plates in a total 100-µL volume in each well. Hemato-
crit and initial parasitaemia were adjusted to 2 and 1.5%, 
respectively. Purified anti-PkDBPα or PkAMA1 rabbit 
IgGs at different concentrations (0.5, 1.0, 1.5, and 2.0 mg/
mL) were added to a 96-well plate (test wells) during P. 
knowlesi sub-culture. Combination of anti-PkDBPα and 
PkAMA1 IgGs was added to make final 0.5 (0.25  mg/
mL each), 1.0, 1.5 and 2.0 mg/mL per well. Control wells 
without antibody (normal invasion well) were set to 
validate the normal invasion ability of the parasite. The 
culture was incubated at 37  °C in a humidified culture 
chamber for approximately 10  h until newly invaded 
ring-stage parasites were found. The non-immunized 
rabbit IgG and anti-Fy6 monoclonal antibody against 
DARC (2C3; 25 μg/mL; a kind gift from Renia L, Singa-
pore Immunology Network-BMSI-A STAR) [32] were 
used as a baseline control. This assay was performed 
independently in duplicate twice.
Determination of parasitaemia by flow cytometry 
and microscopy
Parasites were stained with SYBR Green I (Sigma-Aldrich 
Co.). Briefly, cultures were centrifuged at 500×g for 5 min 
and pellets were washed two times with filtered 1× PBS 
and fixed with 0.05% glutaraldehyde (Sigma-Aldrich Co.) 
for 10  min. Fixed samples were washed twice, stained 
with SYBR Green I at 0.2× dilution for 10  min, and 
washed twice with PBS. The samples were analyzed with 
an Accuri C6 flow cytometer (Accuri cytometers Inc., 
Ann Arbor, MI). In total, 200,000 cells were recorded. 
Percent inhibition was calculated using the following for-
mula: 100 − (100 × (test well (P3)/normal invasion well 
(P3)). After 10  h post-invasion, thin smears were made 
and stained with 10% Giemsa (Merck, Germany) for 
10 min. The infected erythrocytes and the morphology of 
rings were counted and confirmed under a light micro-
scope. More than 20,000 erythrocytes were counted. Per-
cent inhibition was calculated using the same formula as 
for flow cytometry. Two expert persons in the lab were 
recruited in the counting of parasitaemia by microscopy 
to maintain the objectivity and the persons were blinded 
by the information of each smear.
Statistical analysis
All calculations and data analysis were performed with 
GraphPad PRISM 5 (GraphPad Software, Inc., CA, San 
Diego, CA, USA). The independent non-parametric 
Mann–Whitney test was used to determined differences 
between means with 95% CI. Value of p < 0.05 was con-
sidered statistically different. The level of agreement of 
two measuring methods, flow cytometry and microscopy, 
was validated using the Bland–Altman plot [33, 34].
Results
Recombinant protein expression of PkDBPα and PkAMA1
Purified recombinant protein of PkDBPα region II (200–
536 aa.) and PkAMA1 domain I–II (43–387 aa.) have 
been successfully produced and refolded in this study and 
used for rabbit antibody production (Fig. 1a). The bands 
migrated in different mobility between reduced (DTT +) 
and non-reduced condition (DTT −) on the SDS-PAGE 
(Fig. 1b). Anti-PkDBPα, anti-PkAMA1 and anti-His anti-
bodies recognized the recombinant proteins and parasite 
lysate by western blot analysis (Fig. 1c). These results sug-
gest that the native condition of refolded proteins had 
been formed and its antibody can recognize the recombi-
nant protein and native parasite protein.
Recognition of native PkDBPα and PkAMA1 proteins 
from cultured parasites
To validate antibody against those targets, immuno-
fluorescence revealed that those antibodies specifically 
recognized schizont stage of P. knowlesi on apical end 
organelles (Fig.  2a). Human knowlesi-infected patients’ 
serum also showed higher reactivity than that healthy 
individual serum samples for PkAMA1 but not to 
PkDBPα (Fig.  2b; Table  1). These data suggest that 
refolded proteins and antibodies were successfully pro-
duced in this study.
Ex vivo invasion assay
The flow cytometry assay using SYBR Green I dye was 
performed 10  h post-invasion. Total cells were gated 
from uninfected erythrocytes on the basis of forward 
scatter-area (FSC-A) and side scatter-area (SSC-A) 
(Fig. 3a). Then, FSC-A and FSC-H were used to get single 
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cells (Fig. 3b). Infected and uninfected erythrocytes were 
adjusted by FL-1 (FITC) histogram (Fig. 3c). This gating 
strategy clearly distinguished between newly invaded 
rings (P3) and late trophozoites and schizonts (P4), while 
P5 was counted as total parasitaemia (P3 + P4) (Fig. 3d, 
e).
To investigate the invasion ability of PkA1-H.1, schi-
zonts were purified and transferred back to culture in 
the 96-well plates in a 100 μL culture volume (Fig. 4). At 
0  h, schizonts were added to the well at approximately 
1.5% parasitaemia counted by microscopy (Fig.  4a). The 
flow cytometry histogram of showed defined popula-
tions and rings (P3) and schizonts (P4) could be readily 
distinguished (Fig.  4b). After 10  h, newly invaded ring 
stage parasites were found (Fig.  4c, black head arrows), 
but some schizonts were found that had not ruptured 
yet (white head arrow). These two populations were 
observed by flow cytometry with P3 and P4 population 
ratios consistent with the majority of parasites being ring 
stages (Fig. 4d).
In vitro growth inhibition assay (GIA)
In order to know the functional activity of antibodies 
to block PkA1-H.1 invasion into human erythrocytes, 
anti-PkDBPα and anti-PkAMA1 IgGs were added to 
the culture in 96-well plates in different concentrations 
(0.5, 1.0, 1.5 and 2.0 mg/mL). Both antibodies demon-
strated high inhibitory effects on P. knowlesi invasion 
into human erythrocytes in a concentration-depend-
ent manner in contrast to non-immunized IgG where 
little and no inhibition or little induce the invasion 
were observed (Fig.  5a). The anti-DARC monoclonal 
antibody (2C3, 25  µg/mL) almost completely abro-
gated the invasion (90.34 ± 1.22). Flow cytometry and 
microscopic data showed that these two methods were 
comparably effective at distinguishing newly invaded 
rings after 10  h post-invasion (Fig.  5a, b) (Additional 
files 1, 2). The level of agreement of two methods was 
showed with Bland–Altman analysis with less bias 
(0.03808) and standard deviation (SD, 0.1206) (Fig. 5b). 
It indicates that FACS data with SYBR Green I is less 
variable than microscopy. Additive effect of antibodies 
was observed using combination of anti-PkDBPα and 
anti-PkAMA1 in a concentration-dependent manner 
(Fig. 5c). This data indicates that combination of differ-
ent functional antibodies gives more potent than a sin-
gle antibody.
Fig. 1 Schematic structure of PkDBPα and PkAMA1 protein expression. a Schematic of PkDBPα region II (200–536 aa) and PkAMA1 domain I and II 
(43–387 aa). b Reduced (+) and non‑reduced (−) condition of refolded‑PkDBPα and PkAMA1 (2.5 and 5 µg for BSA were loaded per well). c Western 
blot analysis of recombinant proteins PkDBPα and PkAMA1, and PkA1‑H.1 parasite lysate probed with antibodies. His anti‑His antibody, R rabbit 
antibodies, U uninfected RBCs, P parasite lysate. Black head arrows, specific fragmentation bands
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Discussion
The emergence of zoonotic P. knowlesi is thought to be a 
new hurdle in malaria elimination programs, and human 
P. knowlesi cases are on the rise in Southeast Asian coun-
tries [3, 6, 35–37]. Therefore, effective vaccines and 
new therapeutic strategies are needed in these endemic 
countries. The rapid discovery of new vaccine candidates 
in P. falciparum and P. vivax necessitates a functional 
high-throughput assay to evaluate invasion inhibition. 
A growth inhibitory assay or invasion inhibition assay is 
required to evaluate the functional activity of vaccines 
in pre-clinical studies. Evaluation of invasion inhibition 
has been conducted by using target-specific antibodies 
[16, 17, 20, 27]. In this study, a high-throughput invasion 
inhibition assay based on a versatile, reproducible and 
reliable flow cytometry based-assay was used in the criti-
cal evaluation of pre-clinical vaccine candidates against P. 
knowlesi. In order to quantify newly invaded ring-stage P. 
knowlesi parasites after 10 h post-invasion, SYBR Green 
I was used as a nucleic acid dye for enumerating infected 
parasites in this study. This method was applied for eval-
uation of P. knowlesi invasion ability with normocyte in 
a previous study [38]. However, in this study, antibod-
ies were used to evaluate the invasion inhibition against 
P. knowlesi specific and important parasite ligand mol-
ecules, PkDBPα and PkAMA1.
In this study, refolded proteins of PkDBPα and 
PkAMA1 have been successfully produced in E. coli 
system. The correctly folded proteins were confirmed 
by SDS-PAGE analysis as shown in different migration 
mobility of reduced and non-reduced proteins by DTT. 
The antibodies also recognized apical end organelle of 
merozoites and fragmentation of native protein by west-
ern blot. It supports that protein and antibody produc-
tions in this study worked well and different systems 
were used in previous studies [10, 14]. SYBR Green I 
was extensively used in the enumeration of parasitaemia 
because it strongly binds to double-stranded DNA and 
has a low binding affinity for binding single-stranded 
RNA [39–41]. In the 96-well plate, the P. knowlesi ena-
bled to grow and rupture and one cycle of complete 
invasion can be achieved within 24  h [29]. By using 
FL-1 (FITC) flow cytometry histogram, uninfected and 
infected erythrocyte population could be distinguished 
(Fig. 3). Furthermore, to detect new invasion events, two 
Fig. 2 Recognition of PkDBPα and PkAMA1 protein in the parasite 
and human patients. a Immunofluorescence assay of anti‑PkDBPα 
and anti‑PkAMA1 antibodies with PkA1‑H.1 schizont. DAPI, 4′,6‑diami
nidino‑2‑phenylindole. Bars indicate 5 μm. b The humoral immune 
response of PkDBPα and PkAMA1. The IgG response is represented by 
normalized mean fluorescence intensity [MFI]: MFI of the test sample/
[MFI + 2 standard deviations]. P patient serum, H healthy individual 
serum. Black circle, individual patient serum; white circle, healthy 
individual serum; double asterisks, p < 0.001
Table 1 IgG responses of knowlesi-infected patients’ serum samples to PkDBPα and PkAMA1 recombinant proteins
a Positive: the individual who is reactive to its particular antigen
b Negative: the individual who is not reactive to its particular antigen
c Sensitivity: percentage of positive-malaria patient samples
d Specificity: percentage of negative-healthy individual samples
e Normalized MFI: mean fluorescence intensities were divided by a cut-off value + 2 standard deviations above the mean fluorescence intensity of the malaria-naïve 
samples
Samples No. of patient samples (n) Normalized 
 MFIe
No. of healthy samples (n) Normalized 
 MFIe
Positivea Negativeb Total (%)c Positivea Negativeb Total (%)d
PkDBPα 2 13 15 (13.0) 0.76 0 19 19 (100.0) 0.72
PkAMA1 7 8 15 (46.7) 0.92 0 19 19 (100.0) 0.67
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distinct populations from infected erythrocytes were 
clearly defined as newly invaded rings (P3) and tropho-
zoite/schizonts (P4) (Figs. 3, 4). The early ring stages was 
harvested to allow quantification of parasite invasion by 
differentiation in the number of nuclei and amount of 
nucleic acid [39, 40]. SYBR Green I is more versatile dye 
than others because it takes advantages of the brighter 
signal in a flow cytometer of infected erythrocyte count-
ing [42, 43]. This study also reported that FACS analysis 
and microscopy are not different in the enumeration of 
parasitaemia.
The antibodies against the micronemal protein of 
PkDBPα-II had been reported to abrogate the P. knowlesi 
invasion into human and monkey erythrocytes [10]. Sig-
nificant inhibition was also observed with polyclonal 
anti-PvDBP-II antibody in human clinical P. vivax iso-
lates (32.7%) [19]. Likewise in P. vivax, P. knowlesi invasion 
depends on the Duffy antigen on erythrocytes. Blocking 
of DBPα ligand had been thought to block the interac-
tion with DARC receptor on human erythrocytes and its 
interaction is essential for invasion of human erythrocytes 
[44–46]. Thus, human-adapted P. knowlesi A1-H.1 was suc-
cessfully maintained in long-term in vitro culture in recent 
and antibody against PkDBPα-II showed reduction of inva-
sion to human erythrocytes in concentration-dependent 
manner. Blocking of DARC receptor by the anti-Fy6 mono-
clonal antibody (2C3) almost 100% abrogated the invasion 
of P. knowlesi into human erythrocytes similar as previous 
reports [16, 27]. As one of the leading vaccine candidates of 
micronemal protein, apical merozoite membrane antigen 1 
(AMA1) had been widely studied that antibodies to AMA1 
effectively inhibited invasion into human erythrocytes in 
concentration-dependent manner [47–49]. Similarly, anti-
PkAMA1 domain I–II also showed the abrogation of inva-
sion into human erythrocytes in concentration-dependent 
manner, highlighting the essential role of AMA1 in 
Fig. 3 Gating strategy. a Total cell gating strategy from uninfected erythrocytes with forward scatter‑area (FSC‑A) and side scatter‑area (SSC‑A). b 
Single cell gating from uninfected erythrocytes with forward scatter (FSC‑A and FSC‑H). c Histogram flow cytometry of uninfected erythrocytes with 
X‑axis FL1‑A (SYBR Green I). d Giemsa staining of in vitro culture of P. knowlesi. e Histogram flow cytometry of P. knowlesi invasion. P1, total cells of 
being counted; P2, single cells of being counted; P3, early rings; P4, late trophozoites and schizonts; P5, infected erythrocytes (P3 + P4)
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complex with RON2 [14, 15]. Thus, this study has suc-
cessfully confirmed the functional activity of PkDBPα and 
PkAMA1 proteins by E. coli expression system and being 
comparable with previous findings with different systems. 
Interestingly, a combination of PkDBPα and PkAMA1 anti-
body showed the addictive effect to inhibit the PkA1-H.1 
merozoites invasion following the concentration-depend-
ent manner. The expansion of development effective vac-
cine targeting combination of merozoite antigens has 
become a priority to be more effective to control parasites 
to evolve from host immune response [50]. The func-
tional difference of PkDBPα and PkAMA1 in invasion and 
in a combination of its antibody could be more potent to 
abrogate the invasion cascade of P. knowlesi to invade 
human erythrocytes. Moreover, the anti-PkDBPα and anti-
PkAMA1 antibodies were prevalent, but in this study inva-
sion inhibition activity of human antibodies to PkDBPα 
and PkAMA1 was not investigated. PkDBPα seems low 
Fig. 4 Invasion ability in 96‑well plate. a, c Giemsa staining of P. knowlesi before (0 h) and after the invasion (10 h). b, d Histogram flow cytometry of 
before (0 h) and post‑invasion (10 h). White head arrow, schizonts; black head arrows, newly rings
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reactivity may be due to its high genetic diversity in region 
II among Malaysian clinical isolates. Thus, further study is 
needed to show the possible of cross-protection in human 
clinical patients against different strain of P. knowlesi.
Conclusions
In summary, antibodies used in this study have validated 
in vitro invasion inhibition assay by using human-adapted 
P. knowlesi PkA1-H.1 strain parasite. Combination of anti-
bodies with the functional difference may be useful to 
develop the effective vaccine against zoonotic P. knowlesi.
Additional files
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